医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

ECHELON-1 Clinical Trial Evaluating ADCETRIS

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬遺伝学　 TimeLine: Brentuximab Vedotin ECHELON-1 Clinical Trial Evaluating ADCETRIS in Frontline Advanced Hodgkin Lymphoma Takeda and Seattle Genetics to Present Positive

2017年12月10日

Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma

Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma

その他ヘルスヘルスケアヘルス一般腫瘍学臨床試験製薬遺伝学　 TimeLine: Brentuximab Vedotin ECHELON-1 Clinical Trial Evaluating ADCETRIS in Frontline Advanced Hodgkin Lymphoma Takeda and Seattle Genetics Announce Positive

2017年06月26日

Seattle Genetics and Takeda Achieve Target Enrollment in Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Previously Untreated Advanced Hodgkin Lymphoma (HL)

Seattle Genetics and Takeda Achieve Target Enrollment in Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Previously Untreated Advanced Hodgkin Lymphoma (HL)

バイオテクノロジーヘルスケア幹細胞腫瘍学臨床試験製薬遺伝学　 TimeLine: Brentuximab Vedotin ECHELON-1 Clinical Trial Evaluating ADCETRIS in Previously Untreated Advanced Hodgkin Lymphoma Seattle Genetics and Takeda Achieve Target

2015年10月27日